New Frontiers in the Treatment and Management of Heart Failure: A Closer Look at the Role of New Therapies

A continuing medical education activity provided by NAMCP and AAMCN

New Frontiers in the Treatment and Management of Heart Failure: A Closer
Look at the Role of New Therapies is a two-part webinar series

This is Part 1 of the series focusing on New Frontiers in the Treatment and Management of
Heart Failure: A Closer Look at the Role of New Therapies

This activity is an archive from the webinar held May 12, 2021.

This activity is valid from June 1, 2021 to June 1, 2023
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Merck Sharp & Dohme Corp.

Description:
Heart failure (HF) is a common condition that affects approximately 5.7 million people in the United States, and the prognosis for patients with heart failure has traditionally been poor. Projections show that by 2030, the prevalence of heart failure will increase 46 percent from recent estimates. HF is the reason for more than 1 million hospitalizations per year and an estimated $31 billion in costs in the U.S. each year. Fortunately for patients with HF, new and emerging therapeutic options have improved both clinical and economic outcomes for these patients and the system.

Upon completion of this activity, participants will be able to:

  • Examine the unmet clinical needs in heart failure and the impact of inadequately treated disease on physical and mental health, quality of life, costs and work productivity

  • Review the latest clinical evidence regarding the safety and efficacy of sGC modulators for treating patients with HF with reduced ejection fraction (HFrEF)

  • Assess the role of sGC modulators and how they fit into current treatment paradigms for the management of HF

  • Summarize evidence of HF interventions shown to reduce hospitalizations, morbidity, and mortality

     

Faculty: Javed Butler, MD, MBA, MPH
Patrick A. Lehan Chair in Cardiovascular Research
Professor of Medicine and Physiology
University of Mississippi

Disclosure:

Dr. Butler has served as a consultant for Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Meyers Squib, CVRx, G3 Pharmaceutical, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, NovoNordsik, and Vifor. Dr. Butler has served as a speaker for Novartis, AstraZeneca, Boehringer Ingelheim/Lilly, and Janssen.
  Planning Committee:
Bill Williams, MD has no financial relationships with ineligible companies to disclose.
Jeremy Williams has no financial relationships with ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial relationships with ineligible companies to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue